雇主发起的全身癌症筛查的前瞻性研究:日本某癌症筛查项目的成本与结局
在日本滨松一家工程公司开展前瞻性全身癌症筛查项目,包含全身氟-18-2-氟-2-脱氧-D-葡萄糖PET/CT、脑与骨盆MR及腹部超声,每2年一次连续5次。1213名员工中完全参与组543人、部分参与组318人、未参与组352人,分别检出26、9、19例癌症;完全参与组癌症死亡率比为0.11(0.01-0.90),与未参与组比较差异有统计学意义;癌症相关医疗费用以未参与组最高,但差异无统计学意义(P = .108)。
要点
- 全身癌症筛查项目完全参与组与未参与组比较,癌症死亡率比为0.11(0.01-0.90),差异有统计学意义。
- 完全参与组、部分参与组、未参与组分别检出26、9、19例癌症,癌症检出率比无统计学意义。
- 癌症相关医疗费用以未参与组最高,但差异无统计学意义(P = .108)。
诊断标准与关键数值
- 完全参与组与未参与组比较,癌症死亡率比为0.11(0.01-0.90),差异有统计学意义。
- 完全参与组、部分参与组、未参与组分别检出26、9、19例癌症,癌症检出率比无统计学意义。
- 癌症相关医疗费用以未参与组最高,但差异无统计学意义(P = .108)。
局限性
- 癌症检出率比无统计学意义,原文归因于所有员工免费获得的年度其他健康筛查广泛实施,导致基线癌症检出率高。
- 癌症相关医疗费用以未参与组最高,但差异无统计学意义(P = .108)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSES: To determine cancer detection and mortality and its costs associated with employee-initiated, prospective whole-body cancer screening program in an engineering company in Hamamatsu, Japan.
MATERIALS AND METHODS: The program includes whole-body fluorine-18-2-fluoro-2-deoxy-D-glucose PET/CT, brain and pelvis MR, and abdominal ultrasound, offered every 2 years five consecutive times. Employees are free to opt in or opt out anytime. The subjects were divided into the full (five consecutive screenings), partial (more than once and less than five), and no participation groups. The rate ratio of cancer detection rate and cancer-related mortality and cancer-related costs of care were measured. All employees also received other annual health screenings, including chest radiograph or upper gastrointestinal study.
RESULTS: Among 1,213 subjects, 543 employees were under full participation, 318 were under partial participation, and 352 were under no participation. In all, 26, 9, and 19 cancers were detected from the full participation, partial participation, and nonparticipation groups, respectively. No statistical significance was observed in the cancer detection rate ratio. The rate ratio of cancer-related deaths was 0.11 (0.01-0.90) for the full participation group compared with the nonparticipation group, and the difference was statistically significant. The cost of cancer-related care was highest among the nonparticipation group; however, the difference was not statistically significant (P = .108).
CONCLUSION: Whole-body cancer screening can successfully reduce cancer-related mortality and costs of cancer-related care. The cancer detection rate was not significantly improved because of broad implementation of additional annual health screenings offered to all employees at no cost, resulting in the high baseline cancer detection rate.
引用
- Anzai Y, Nishizawa S, Shinke T, et al. Prospective Employer-Initiated Whole-Body Cancer Screening-Costs and Outcomes of a Cancer Screening Program in Japan. J Am Coll Radiol. 2021. PMID: 33413890. doi:10.1016/j.jacr.2020.09.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。